Every 8-K that BIOLARGO INC (BLGO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BLGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLGO filings page.
BioLargo, Inc. (BLGO) filed an amendment to provide the full transcript of a September 10, 2026 shareholder town hall and business update. Management described a portfolio model that “manufactures companies” around proprietary technologies, including wound-care subsidiary Clyra Medical, the Cellinity battery platform, PFAS water treatment, engineering services, and a new consumer-products group and Tũ Nipi Water Solutions alliance.
Leaders highlighted that core revenue (excluding the Pooph odor-control line) has been rising quarter to quarter, supported by the engineering segment, while consolidated results were heavily impacted by the loss of Pooph and a related ~$4 million write-down. The parent company’s overhead is about $250,000 per month, with over $2 million in cash and roughly 86% of recent capital raised at the subsidiary level. Management cited indicative valuations of about $100 million for Clyra (BioLargo owns 48%) and about $33–34 million from a prior Cellinity financing, arguing that these alone exceed BLGO’s market cap. Near-term goals include launching the BioLargo CPG brand in October, converting Clyra’s new distributors and a large yet-undisclosed partner into orders, winning larger PFAS and industrial-water projects (often $5–40 million in scope), and progressing minerals and oil-sands projects with partners.
BioLargo, Inc. (BLGO) furnished an investor slide presentation in connection with a webcast investor conference held on September 10, 2026 at 1:00 PM Pacific Time. The slides are provided as Exhibit 99.1 under a Regulation FD disclosure and are expressly treated as “furnished,” not “filed,” under federal securities laws.
The company states that the information in this report and its exhibits will not be incorporated by reference into other SEC filings and that it undertakes no obligation to update the disclosed information, directing readers to the “Safe Harbor Act” discussion in the exhibit for important forward-looking statement information.
BioLargo, Inc. furnished a shareholder town hall transcript and investor summary describing progress and challenges across its five operating subsidiaries, without providing new formal financial results. CEO Dennis Calvert outlined strategic milestones, capital structure, and commercialization plans.
He said BioLargo’s market cap is about $50 million with roughly 320 million shares outstanding, and estimated subsidiary Clyra Medical at roughly $100 million, of which BioLargo owns 48% plus a 6% gross sales royalty. Recent milestones cited include a first municipal PFAS-removal installation in Lake Stockholm, New Jersey, a $1.2 million mineral-extraction engineering contract, new Clyra distribution deals including Al Hikma in MENA, and a memorandum of understanding with global water firm Aquatech for PFAS projects.
Calvert emphasized capital efficiency, stating about $50 million of invested capital has built five subsidiaries, two already commercial. He discussed the loss of Pooph-licensed odor-control revenue, ongoing litigation to protect intellectual property, and efforts to reposition that asset. He also highlighted the Cellinity sodium-based battery venture, describing long-life, non-degrading storage as a national-scale opportunity, and reiterated his view that the stock is undervalued as the company enters what he called a harvesting phase.
BioLargo, Inc. filed a current report announcing that CEO Dennis P. Calvert will participate in a shareholder town hall meeting on May 5, 2026 at 1:00 PM Pacific Time, hosted on the BioLargo Shareholder Community Discord channel.
The town hall will feature a brief company update followed by a Q&A session with shareholders. The meeting will be recorded and a transcript will be filed on Form 8‑K prior to the market open the next day. The company also includes standard forward-looking statement and Safe Harbor language referencing risks described in its most recent SEC filings.
BioLargo, Inc. entered into a purchase agreement and related registration rights agreement with Clearthink Capital Partners, LLC that gives BioLargo the right to sell up to $10.0 million of common stock to Clearthink over a 36‑month period, subject to conditions.
After SEC effectiveness of a resale registration statement, BioLargo may, at its sole discretion, direct Clearthink on selected trading days to buy shares in amounts up to the lesser of $500,000 or 300% of the recent average trading value, with a minimum of $25,000 and at least five business days between notices. The purchase price per draw is based on the average of the two lowest closing prices over the prior eight trading days.
As consideration for this committed equity facility, BioLargo issued 500,000 commitment shares of common stock to Clearthink without receiving cash proceeds. Clearthink is capped at 9.99% beneficial ownership and is prohibited from short sales or net short hedging, while BioLargo can terminate the arrangement on one business day’s notice. The initial issuances rely on private offering exemptions under Section 4(a)(2) and Rule 506(b).
BioLargo, Inc. used this report to share an investor slide deck and press release summarizing its 2025 performance and outlook. Management described 2025 as a year of both accomplishment and adversity, including the termination of its largest customer’s license and the related loss of revenue.
The company highlighted a $3.9 million cash balance at year end 2025, a 98% increase in engineering services revenue, and commercialization progress across several business segments. Subsidiaries Clyra Medical Technologies and Cellinity Battery raised capital in 2025, and leadership expressed optimism about 2026 opportunities in surgical products, PFAS water treatment, and battery energy storage.
BioLargo, Inc. reported that on November 14, 2025 two company officers agreed to convert an aggregate $99,901 of unpaid salary and unreimbursed business expenses into common stock. The shares were issued at a price of $0.16 per share, resulting in an aggregate issuance of 624,383 shares of BioLargo common stock. These shares are subject to a Lock-Up Agreement dated as of the issuance date, meaning they cannot be sold until BioLargo reports at least $40 million in consolidated gross revenue for any reported period, or its market capitalization exceeds $300 million, or the company undergoes a change in control.
BioLargo, Inc. (BLGO) furnished an investor presentation under Item 7.01 (Regulation FD). The company plans to present the slide deck attached as Exhibit 99.1 during an investor webcast on November 14, 2025 at 1:30 PM Pacific Time.
The information is expressly stated as furnished, not filed, and is not subject to liability under Section 18 of the Exchange Act nor incorporated by reference into other filings. The company notes Safe Harbor language applies to forward-looking statements in the slides. Exhibits include 99.1 (slide deck) and 104 (Cover Page Inline XBRL).
BioLargo, Inc. (BLGO) furnished investor presentation materials under Item 7.01 (Regulation FD). The company plans to present the slides attached as Exhibit 99.1 at the LD Micro Main Event XIX at the Hotel del Coronado in San Diego on October 20 at 2:00 p.m. Pacific Time.
The information in Item 7.01 and Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, is not incorporated by reference into other SEC filings, and may be updated through future public disclosures.
BioLargo, Inc. disclosed that its long‑standing license and manufacturing relationship with Pooph Inc. has broken down, and it has issued notice revoking Pooph’s license and terminating the License Agreement with 150 days’ notice after Pooph failed to pay agreed royalties and product invoices. Pooph has stated it will stop ordering from BioLargo, pursue its own formula for Pooph‑branded products, and terminate the Preferred Master Manufacturing Agreement, which BioLargo disputes, citing its contractual right to withhold product when payment terms were not met.
BioLargo also reported that a $3,486,000 note receivable tied to Pooph royalties and product invoices on its June 30, 2025 balance sheet may need to be written down, and management expects any impairment of this asset to be substantial, signaling a potentially significant financial hit related to this customer relationship.